This is the authors' abstract. We don't add key points for this paper.
Crystallization plays an important role in enhancing the stability and purity of pharmaceutical compounds. A cap-dependent endonuclease inhibitor (CDEI) for influenza treatment was crystallized. Solvent evaporation and slurry conversion using various organic solvents induced crystallization into Form I, II, and III of the CDEI. Single-crystal X-ray diffraction (SXRD) confirmed solvate formation, and the intermolecular interactions between CDEI and the organic solvents were characterized. Residual solvents are toxicologically regulated in pharmaceutical applications, and alternative crystal forms have been studied. Racemates and enantiomers of propylene glycol (PG), a traditional pharmaceutical excipient, have been used as alternative crystallization solvents. Slurry conversion in RS-PG, R-PG, and S-PG resulted in Form I; however, only S-PG crystallized slowly. SXRD revealed a hydrogen bond between CDEI and the PGs. Further interactions between the PGs were observed only for the S-PG solvate. To overcome the difficulty of handling PG owing to its high viscosity, PG solvates were crystallized in other organic solvents. All PG solvates were obtained by slurry conversion of CDEI in toluene, followed by the addition of PGs via guest exchange of the solvents from toluene (Form III) to the PGs (Form I). We conclude that PGs are reasonable coformers for the design of multicomponent pharmaceutical crystals.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ueda et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: